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E D I T O R I A L
Prevention of hypophosphatemia during continuous renal
replacement therapy—An overlooked problem
Abstract
Hypophosphatemia is a common and potentially serious complication
occurring during continuous renal replacement therapy (CRRT). Phos-
phate supplementation is required in the vast majority of patients
undergoing CRRT, particularly beyond the first 48 hours. Supplemen-
tation can be provided either as a standalone oral or parenteral
treatment or as an additive to CRRT solutions. Each approach has
advantages and disadvantages, and clinicians must weigh the individ-
ual factors most relevant in their practice setting. Currently there are
no consensus protocols for phosphate replacement in CRRT, and
many centers replete phosphate in response to hypophosphatemia
as opposed to pre-emptively. Repletion protocols have also been
challenged in recent years by shortages in injectable phosphate solu-
tions. More recently a commercially available phosphate-containing
CRRT solution was approved in the United States, but there has
been limited clinical experience with this product. In this review, we
present recommendations for phosphate repletion in CRRT to pre-
vent hypophosphatemia, and describe our experience using phos-
phate-containing CRRT solutions.
1 | INTRODUCTION
Continuous renal replacement therapy (CRRT) has emerged as the
recommended dialysis modality for critically ill patients with severe
renal failure, particularly those with hemodynamic instability.1 Com-
pared to standard intermittent hemodialysis (IHD) therapy, CRRT
provides greater overall solute clearance and fluid balance control.2
While IHD clearance achieves rapid correction of biochemical abnor-
malities with subsequent accumulation between treatments, CRRT
aims to provide a more stable clearance that approaches the physio-
logic state while maintaining fluid balance.
Patients undergoing IHD, in either the acute or chronic setting,
frequently have persistent hyperphosphatemia and require dietary
phosphate-binders to reduce serum phosphate levels. In contrast,
CRRT is associated with a risk of developing hypophosphatemia.
Recent studies have linked CRRT-related hypophosphatemia to
adverse outcomes in critically ill patients, including prolonged
mechanical ventilation requirements, longer hospital length of stay,
and mortality.3-5 The approach to managing this complication varies
widely among programs, with most centers providing exogenous
supplementation while others pre-emptively add phosphate to exist-
ing CRRT solutions. Both of these practices have been jeopardized
in recent years due to shortages of intravenous phosphate solu-
tions.6 More recently, a commercially available phosphate-containing
CRRT solution has become available in the United States.
In this article, we will discuss the physiology of phosphate bal-
ance during renal replacement therapies and review the literature on
hypophosphatemia in CRRT patients. We will present the advantages
and disadvantages of different phosphate repletion strategies in
patients undergoing CRRT, and provide recommendations for reple-
tion strategy. We will also describe our single-center experiences
using phosphate-added CRRT solutions, and discuss the potential
role of newly available commercial phosphate-containing solutions.
2 | PHOSPHATE PHYSIOLOGY
In biologic systems, phosphorus exists in both organic (e.g. in phos-
pholipids) and inorganic (e.g. ionized) forms. Inorganic phosphate
plays a key role in many critical biological processes. For example,
phosphorylation and dephosphorylation are integral steps in cellular
energy storage and usage through the conversion between adeno-
sine diphosphate (ADP) and adenosine triphosphate (ATP).
Bone, in the form of hydroxyapatite, is the largest reservoir of
phosphate in the body. Outside of bone, most phosphate is stored
intracellularly and, similar to potassium, serum levels may not accu-
rately reflect available stores. Under normal physiologic conditions,
dietary phosphate is readily absorbed in the small intestine, filtered
at the glomerulus, and reabsorbed in the proximal tubule. The degree
of tubular reabsorption is the key factor in maintaining serum levels,
and is regulated by parathyroid hormone (PTH) and fibroblast growth
factor 23 (FGF-23).7 With mild renal impairment, phosphate filtration
decreases but a compensatory decrease in tubular reabsorption can
maintain normal levels. In advanced renal insufficiency (acute or
chronic), phosphate clearance becomes impaired enough to result in
overt hyperphosphatemia.8 In patients with end stage renal disease
(ESRD), hyperphosphatemia is an independent risk factor for mortal-
ity.9
Consequently, removal of phosphate is one important goal for
dialysis therapy in patients with ESRD. Adequacy of dialysis clear-
ance has traditionally focused on urea kinetics, but this approach
may not apply to molecules with different characteristics.10 In the
case of phosphate, a rate limiting step to dialytic clearance is the
slow equilibration between the intracellular and extracellular com-
partments. Indeed, rebound increases in phosphate levels are typi-
cally seen following a standard IHD treatment, and improved
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phosphate control has been described with alternative dialysis regi-
mens such as nocturnal or daily dialysis.11,12 Given these limitations,
for patients on standard IHD (e.g. thrice weekly schedule) a mainstay
of hyperphosphatemia management is the use of oral phosphate bin-
ders to decrease gastrointestinal absorption because thrice weekly
IHD alone usually cannot clear sufficient phosphate to maintain tar-
get serum levels.
3 | RATIONALE FOR PHOSPHATE
REPLETION IN CRRT
In contrast to IHD, the continuous nature of CRRT avoids any
rebound effect and allows for constant phosphate clearance as com-
partmental equilibration occurs.13 However, dialysis solutions (com-
mercially available dialysate and intravenous ultrafiltrate replacement
solutions) traditionally have not contained any phosphate, probably
because they were originally based on the electrolyte needs of ESRD
patients. Therefore, unlike IHD, the primary phosphate disturbance
complicating CRRT is hypophosphatemia.
In their single-center experience, Demirjian and colleagues
observed a 27% incidence of hypophosphatemia (serum phosphate
<2 mg/dL) during CRRT.3 Hypophosphatemia was associated with
higher risk for prolonged respiratory failure needing tracheostomy,
but there were no differences in mortality at 28 days. The associa-
tion between hypophosphatemia and prolonged ventilator require-
ments has also been observed in critically ill patients not requiring
dialysis.14,15 More recently, Yang and colleagues analyzed a cohort
of 760 patients undergoing CRRT and observed hypophosphatemia
(<2.5 mg/dL) in 69%, and severe hypophosphatemia (<1.0 mg/dL) in
14%.4 Patients with a higher proportion of CRRT treatment days
complicated by hypophosphatemia had greater mortality. In a sec-
ondary analysis of the RENAL randomized clinical trial, Bellomo and
colleagues reported that 32% of patients undergoing CRRT devel-
oped hypophosphatemia (<1.88 mg/dL), and hypophosphatemia was
more likely with higher doses of CRRT.16 They also observed that
peak incidence of hypophosphatemia occurred on day 3 or 4 of
CRRT.
Thus, hypophosphatemia commonly complicates CRRT and
appears to be associated with adverse clinical outcomes. Notably,
hypophosphatemia frequently developed in the setting of exogenous
supplementation (either enteral or parenteral), and despite many
patients starting out with hyperphosphatemia. In order to avoid
hypophosphatemia, clinicians must therefore be vigilant of this risk
and take a proactive approach to supplementation.
4 | APPROACHES TO PHOSPHATE
REPLETION IN CRRT
Table 1 summarizes the various approaches to phosphate repletion
in patients undergoing CRRT, along with their advantages and dis-
advantages. At present, most centers utilize exogenous supplemen-
tation, either oral or parenteral. Supplementation can be a part of
a patient’s nutritional prescription (e.g. in enteral feeding or total
parenteral nutrition), or as dedicated phosphate repletion using
intravenous piggyback infusions. In the latter case, phosphate is
often administered as part of a hospital’s electrolyte protocol. One
of the advantages of exogenous supplementation is that the physi-
cian has the ability to titrate phosphate to the needs of the clini-
cal situation. However, to avoid hypophosphatemia a high level of
vigilance is required, particularly if supplementation is provided by
physician order on an ad hoc basis and outside of an established
protocol. Even with the use of an electrolyte repletion protocol,
there are potential pitfalls. The risk of hypophosphatemia increases
when lab draws are infrequent (e.g. once daily), when the thresh-
old level of phosphate for intervention is low, when the amount
of supplementation is insufficient, and probably when the route of
administration is oral (because of inconsistent absorption). Medical
centers have typically developed their own electrolyte supplemen-
tation protocols, and at present there are no published consensus
protocols.
TABLE 1 Approaches to phosphate supplementation in patients undergoing CRRT
Approach Advantages Disadvantages
Physician guided
supplementation
• Use of clinical judgment
• Ease of titration
• Oral/enteral or intravenous options
can be used synergistically
• Relies on high level of vigilance and regular laboratory data
• Vulnerable to solution shortages
Protocol-guided
supplementation
• Automated
• Easily titratable supplementation
• May promote less vigilance among clinicians
• Depending on protocol characteristics, may be reactive to
hypophosphatemia instead of proactive
• Vulnerable to solution shortages
CRRT solution
supplementation
• Provides steady-state base phosphate level
• Titratable
• Potential risk for errors and/or contamination
• Increased pharmacy workload
• Vulnerable to solution shortages
Commercial phosphate-containing
CRRT solution
• Provides steady-state base phosphate level
• No pharmacy manipulation required
• Fixed level and nontitratable
CRRT, continuous renal replacement therapy.
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In Table 2, we present recommendations for initial phosphate
supplementation during CRRT prescribed at standard recommended
effluent doses of 20-25 mL/kg/h. Because the immediate risks of
hypophosphatemia outweigh the risks of mild to moderate hyper-
phosphatemia, this protocol emphasizes initiation of supplementation
at normal to mildly high phosphate levels in order to avoid
hypophosphatemia altogether. In contrast, many currently employed
protocols focus on repletion only when phosphorus levels have fal-
len to 2.5 mg/dL or lower. After initiation, subsequent repletion
should be titrated to maintain phosphorus levels in the normal range.
Both oral (when patients are tolerating enteral feeding) and intra-
venous supplementation can be used. Use of low phosphate feeding
formulations is not recommended during CRRT. In addition, when
phosphate levels are declining, it is important to consider increasing
the frequency of monitoring, which allows greater opportunity to
avoid overt hypophosphatemia. This recommended protocol is not
meant to replace clinical judgment, and clinicians should take into
account rate of phosphate change and adjust supplementation
accordingly. For example, patients on higher effluent doses of CRRT
may require augmented supplementation, while patients with a cell
lysis syndrome may not require any supplementation.
The other major approach to prevent hypophosphatemia is to
include phosphate in the CRRT solutions. A key advantage to this
approach is the ability to maintain a basal level of phosphate that, in
theory, patients will not fall below. For example, if CRRT dialysate
has a phosphate concentration of 4 mg/dL (1.3 mmol/L), a hyper-
phosphatemic patient will have a continual clearance phosphate until
the serum concentration reaches 4 mg/dL at which time net
phosphate clearance will cease. Similarly, a hypophosphatemic CRRT
patient would have a continual increase in serum phosphate until
their value reaches the 4 mg/dL equilibrium point. Until recently,
centers pursuing this approach have had to add supplemental elec-
trolytes to solutions under sterile conditions to avoid risk of contam-
ination. The availability of commercial phosphate-containing
solutions allows for off-the-shelf use of CRRT solutions without
additional manipulation; however, the phosphate concentration is
fixed in these solutions and is not easily titratable.
5 | OUR SINGLE CENTER EXPERIENCE
As an internal quality assessment project, we performed a retrospec-
tive analysis of 62 consecutive adult patients (36 males and 26
females, mean age 57.5  11.9 years) who received CRRT for at
least 3 days (mean duration 6.9  3.5 days). At the time of this anal-
ysis, physicians were administering phosphate as oral or intravenous
supplementation, or as an addition to dialysate based on clinical
judgment. Figure 1 illustrates that on the first day of CRRT mean ini-
tial serum phosphorus concentrations were elevated 6.0  3.4 mg/
dL but highly variable. Normophosphatemia was achieved in most
patients by day 3, and by day 4 more than half of the patients
required some type of phosphate supplementation. The approach
chosen most commonly by physicians was the addition of phosphate
to the dialysate (>50% of patients).
We observed similar results when examining our experience with
pediatric patients undergoing CRRT. Pediatric patients, particularly
very young ones, may not have the same phosphate stores as adults
and consequently their phosphate supplementation needs in CRRT
may differ as well. We compiled the laboratory profiles of 26 consecu-
tive children (mean age 7.3  7.6 years) who received CRRT in our
institution using a pharmacy-made, phosphate-containing (2 mmol/L;
6.2 mg/dL) dialysate. Soon after this analysis, our institution switched
to exclusive use of a commercial, nonphosphate-containing dialysate,
to which physicians could order the addition of phosphate. We fol-
lowed the first 32 pediatric patients receiving this phosphate-free dia-
lysate. They were similar in age to the baseline group (9.1  7.4 years)
and received treatment for 12.8  13.4 days. While phosphate control
was achieved using both phosphate-containing and phosphate-free
dialysate, subjects receiving phosphate-free dialysate were very likely
to require the other forms of phosphate supplementation (Figure 2).
By day 4 over 90% of patients starting with the phosphate-free dialy-
sate required added phosphate to the dialysate; over half also were
receiving other phosphorus supplementation in the form of oral and/
or intravenous phosphate. In subjects started with the phosphate-con-
taining dialysate, few required extra phosphate in the dialysate and
only about a quarter received any intravenous or oral phosphate to
maintain desired serum phosphate concentrations. As a result of these
observations, our current standard of practice is to routinely add phos-
phate to our CRRT solutions (target concentration either 0.75
[2.3 mg/dL] or 1.5 mmol/L [4.6 mg/dL]) in order to limit the risk of
hypophosphatemia.
TABLE 2 Recommended protocol for exogenous phosphate
supplementation in patients initiating continuous renal replacement
therapy using nonphosphate containing solutions
Pre-CRRT
phosphate
level
Oral repletion
regimena
(if tolerating
enteral)
IV repletion
regimenb
Frequency of
phosphorus
monitoring
>5.5 mg/dL None None Q24h
4-5.5 mg/dL 1 tab Q12h None Q12-24h
2.5-4 mg/dL 1 tab Q8h None if
tolerating oral.
If unable to
tolerate
oral, then
10 mmol IV Q12h.
Q6-12h
<2.5 mg/dL 1 tab Q6h 20-40 mmol IV
daily until
normal levels
achieved
Q6h
aBased on sodium phosphate/potassium phosphate tablets, each of
which contains 8 mmol phosphate, 1.1 mEq potassium and 13 mEq
sodium. Oral repletion may be reduced if patient is tolerating full diet.
bIntravenous phosphate should be given as sodium phosphate unless
hypokalemia is also present, in which case potassium phosphate can be
used.
CRRT, continuous renal replacement therapy.
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6 | SPECIAL CONSIDERATIONS FOR
PHOSPHATE-CONTAINING CRRT
SOLUTIONS
Several important considerations regarding phosphate supplementa-
tion of CRRT solutions are worth noting. First, in recent years there
have been shortages of a variety of injectable solutions, including
phosphate.6,17 Of course, such shortages will also impact exogenous
supplementation and may necessitate increased reliance on oral/en-
teral approaches. During such periods, physicians and pharmacists
must work together to identify alternative options and revise
approaches as necessary.18
Secondly, the United States Pharmacopeia regulations provide
guidance on appropriate pharmaceutical compounding practices (USP
chapter 797). Appropriately, electrolyte additions to CRRT solutions
must be done under controlled sterile conditions and using proper
techniques. This requires pharmacy involvement and cannot be done
by bedside nursing, so engagement and buy-in from the hospital
pharmacy team is critical. Even with proper techniques, contamina-
tion remains a theoretical concern. Furthermore, particularly in high-
F IGURE 1 Phosphate supplementation
and serum phosphate values in 62 adult
patients receiving continuous venovenous
hemodialysis. Mean serum phosphate
levels denoted by ● and the error bars on
each day denote standard deviation. Δ
denotes percentage of patients who
received phosphate into their dialysate.
▲denotes percent of patients who
received exogenous phosphate
supplementation either by oral or
parenteral routes of administration
F IGURE 2 Daily phosphate
supplementation requirements in pediatric
patients receiving continuous renal
replacement therapy (CRRT) when a
phosphate-free dialysate was used (n = 32)
or a phosphate-containing dialysate was
used (n = 26). Pediatric patients receiving
CRRT with a phosphate-free dialysate
required substantially more phosphate
supplementation than did those who were
receiving a pharmacy-compounded
dialysate containing 2 mmol/L (6.19 mg/
dL) phosphate. By day 4 of CRRT, nearly
all patients originally started on phosphate-
free dialysate needed to receive phosphate
in their dialysate. Intravenous/Oral
phosphate supplementation rates were
consistently higher for patients receiving
phosphate-free dialysate
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volume and high-acuity settings, there is a risk for human error with
either incorrect additives or incorrect dosages delivered. Indeed, dial-
ysis solutions are considered “high-alert” medications by the Institute
of Safe Medication Practices.19 Patients undergoing CRRT are criti-
cally ill and vulnerable, and such errors can be devastating.20-22
Thirdly, the economic implications of different approaches to
phosphate supplementation have not, to our knowledge, been fully
explored. In addition to comparing the direct costs (e.g. commercial
phosphate-containing solutions versus commercial solutions plus
individual additives versus commercial solutions plus supplementa-
tion), one must account for the workload associated with custom
compounding CRRT solutions. This latter impact will vary by the
characteristics of a given medical center, including personnel costs
and volume of CRRT care. In our medical center, we have also
observed significant medical waste of CRRT solutions which we
believe is in part related to a limited shelf life for use (12 hours)
after manipulation for electrolyte additives.23 Another difficult to
quantify consideration is the potential cost from adverse events
should they occur.
Lastly, a detailed examination of the recently available phos-
phate-containing CRRT solution (Phoxillum, Baxter International Inc.)
in the United States is warranted. A similar formulation has been
available in Europe for a number of years, where published experi-
ence suggests efficacy in preventing hypophosphatemia.24,25 Studies
have also demonstrated the stability of phosphate in CRRT solutions
and lack of significant precipitation with calcium.26-29 An important
difference, however, is that the phosphate concentration of the
approved U.S. CRRT solution is 1.0 mmol/L (3.1 mg/dL) compared
to 1.2 mmol/L (3.7 mg/dL) in the European formulation. While this
concentration is within the normal range for phosphate, critically ill
patients may have higher phosphate needs. This level may also be
inadequate for use in pediatric populations who have higher normal
phosphate levels. Additional clinical experience with this solution is
needed to assess whether exogenous supplementation may still be
required. Hospital pharmacy and therapeutics committees will need
to assess all these considerations when making their formulary deci-
sions for these new products.
7 | SUMMARY/CONCLUSION
In summary, hypophosphatemia is a common complication among
patients undergoing CRRT and can adversely impact patient out-
comes. Unfortunately, hypophosphatemia remains a somewhat over-
looked problem, based on the continued high incidence reported in
the literature and the fact that most repletion protocols emphasize
replacement once hypophosphatemia has developed. A variety of
approaches to preventing hypophosphatemia exist, each with their
own advantages and disadvantages. Repletion protocols should aim
to maintain normophosphatemia and therefore begin supplementa-
tion at normal serum phosphorus levels. Based on our experiences,
we advocate for addition of phosphate to CRRT solutions in order
to prevent development of hypophosphatemia. The recent
availability of a commercial phosphate-containing CRRT solution may
provide a balance between hypophosphatemia risk, workload and
patient safety. However, additional clinical experience with these
new solutions is needed.
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